Search details
1.
Computational analysis of kinase inhibitor selectivity using structural knowledge.
Bioinformatics
; 35(2): 235-242, 2019 01 15.
Article
in English
| MEDLINE | ID: mdl-29985971
2.
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor.
Br J Clin Pharmacol
; 85(8): 1751-1760, 2019 08.
Article
in English
| MEDLINE | ID: mdl-30973970
3.
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Breast Cancer Res
; 20(1): 109, 2018 09 05.
Article
in English
| MEDLINE | ID: mdl-30185228
4.
Genome-wide discovery of drug-dependent human liver regulatory elements.
PLoS Genet
; 10(10): e1004648, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-25275310
5.
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin.
Proc Natl Acad Sci U S A
; 111(27): 9983-8, 2014 Jul 08.
Article
in English
| MEDLINE | ID: mdl-24961373
6.
Renal transporters in drug development.
Annu Rev Pharmacol Toxicol
; 53: 503-29, 2013.
Article
in English
| MEDLINE | ID: mdl-23140242
7.
Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors.
Nat Cancer
; 4(4): 485-501, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36997747
8.
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.
Pharmacogenet Genomics
; 20(11): 677-86, 2010 Nov.
Article
in English
| MEDLINE | ID: mdl-20940534
9.
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma.
Clin Cancer Res
; 26(8): 1820-1828, 2020 04 15.
Article
in English
| MEDLINE | ID: mdl-31937616
10.
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Cancer Chemother Pharmacol
; 84(6): 1257-1267, 2019 Dec.
Article
in English
| MEDLINE | ID: mdl-31542806
11.
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Clin Cancer Res
; 25(11): 3220-3228, 2019 06 01.
Article
in English
| MEDLINE | ID: mdl-30770348
12.
Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction.
Drug Metab Dispos
; 36(11): 2355-70, 2008 Nov.
Article
in English
| MEDLINE | ID: mdl-18669588
13.
A validated surrogate analyte LC-MS/MS assay for quantitation of endogenous kynurenine and tryptophan in human plasma.
Bioanalysis
; 10(16): 1307-1317, 2018 Aug 01.
Article
in English
| MEDLINE | ID: mdl-30141341
14.
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
J Immunother Cancer
; 6(1): 61, 2018 06 20.
Article
in English
| MEDLINE | ID: mdl-29921320
15.
Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) Pharmacokinetics.
CPT Pharmacometrics Syst Pharmacol
; 6(11): 747-755, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28748626
16.
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Eur J Cancer
; 86: 186-196, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28992562
17.
The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers.
Clin Pharmacokinet
; 55(4): 495-506, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-26507723
18.
The Patient-Centered Future of Clinical Pharmacology.
Clin Pharmacol Ther
; 107(1): 72-75, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31751490
19.
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
J Med Chem
; 56(3): 781-795, 2013 Feb 14.
Article
in English
| MEDLINE | ID: mdl-23241029
20.
Consequences of POR mutations and polymorphisms.
Mol Cell Endocrinol
; 336(1-2): 174-9, 2011 Apr 10.
Article
in English
| MEDLINE | ID: mdl-21070833